Die 6 USD sind zum Greifen nahe.  

sind ja viele Moorhühner hier drin *g*.  

Da cytori gerade 22,5 mio Aktien hat und 134 mio USD wert ist, muß sich der Kurs entweder noch mehrfach verdoppeln, oder die ganze Technologie muß floppen.

Immer mehr scheinen es zu begreifen, was es bedeutet, als erste Stammzellenfirma ein zugelassenes Verfahren am Markt zu haben.

Stammzellen aus eigenerm Fettgewebe, keinerlei ethisches Problem.

Ich denke als Spekulative Beimischung hat Cytori eine gute Existenzberechtigung. ;-)  

Seit Dezember steigt die Aufmerksamkeit.
Jetzt sinds noch die frühen Vögel, aber das wird schon noch werden.

Über 6,50 bis 7 sollte CYTX zügig bis 10 weiter steigen. Günstig ist jetzt, dass die Kassenlage bis 2008 gesichert ist bis dann auch die Kommerziellen Anwendungen und Kooperationszahlungen die Finanzen stabil halten sollten.

 

Allerdings hauptsächlich die, die Embryonalzellen nutzen und STEM wegen dem Kürzel *g*

CYTX legt dagegen zu.

Stem cell stocks dive on Senate vote
Many stem-cell-related biotechs unaffected by vote on funding but shares get hit nonetheless; the Cytori exception.
By Aaron Smith, CNNMoney.com staff writer
April 12 2007: 12:14 PM EDT

NEW YORK (CNNMoney.com) -- Biotechs specializing in stem cell research took a hit Thursday after the Senate voted to remove a ban on federal funding for embryonic stem cell research but not by a wide enough margin to overcome an expected presidential veto.

The declines came even though only two of the companies, Geron and Advanced Cell Technologies, use embryonic stem cells. Geron's (down $0.14 to $7.42, Charts) stock dropped nearly 2 percent and Advanced Cell, which is traded over-the-counter, slipped 1 percent.

The other biotechs use stem cells from adult tissue.

StemCells, Inc., (down $0.13 to $2.73, Charts) which according to analysts experiences big swings on these issues due to its distinctive ticker symbol - STEM - tumbled about 4 percent in early trading though it later came off its lows.

Osiris Therapeutics (down $0.10 to $15.96, Charts), which extracts stem cells from bone marrow as opposed to embryos, also sank 4 percent initially and was off about 2.5 percent two hours into the session. Aastrom Biosciences (down $0.04 to $1.46, Charts), which also uses adult tissue, lost 1.5 percent.

Cytori Therapeutics (up $0.10 to $6.03, Charts), which derives its stem cells from fat tissue, bucked the trend and rose 2 percent.
Rats walk but money waits

Jose Haresco, analyst for the investment research firm Merriman Curhan Ford, said day traders were buying and selling "off the political momentum" of the Senate vote, even though "it's not related to the companies and the fundamentals of the science at all."

The Senate voted 63-34 on Wednesday to remove President Bush's 2001 restrictions on federal funding for research involving embryonic stem cells. But the vote failed to reach the two-thirds majority needed to override Bush's expected veto.
Robots grab chunk of prostate surgery biz

In a statement issued after Wednesday's 63-34 vote, Bush said he would veto the new bill, saying it "crosses a moral line that I and many others find troubling."

Stem cells serve as a repair system for the body. They can morph into other types of cells, according to the National Institutes of Health, and scientists hope to harness the cells to repair damage from crippling injuries and diseases.

©

Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.  

http://www.clinicaltrials.gov/ct/show/NCT00442806?order=1

A Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Patients With ST-Elevation Myocardial Infarction

This study is not yet open for patient recruitment.
Verified by Cytori Therapeutics February 2007

Study start: May 2007; Expected completion: June 2011
Last follow-up: May 2011; Data entry closure: June 2011

-> Six Month Follow Up erwarte ich für Mitte 2008 (das sind die Daten, mit auf deren Basis man die Pivotals für die EU und die USA )initiieren möchte


Da wird es also im Mai wahrscheinlich Meldung geben. :-)

 

Man kann auch sagen, dass der Kursverlauf enttäuschend ist. :-(  

Der Kurs scheint sich aber schon wieder zu erholen...

©

Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.  

Sector Snap: Stem Cell Developers
Monday May 7, 2:20 pm ET
Stem Cell Developers' Shares Rise Following a Marketplace Overview From Barron's

NEW YORK (AP) -- Shares of biotechnology companies developing stem cell-based treatments jumped Monday following a report in Barron's on the technology's possibilities.

Shares of StemCells Inc. rose 12 cents, or 4.8 percent, to $2.63 in midday trading. Shares of Osiris Therapeutics Inc. rose 11 cents to $15.05, while shares of Geron Corp. rose 21 cents, or 2.8 percent, to $7.64 and shares of Cytori Therapeutics Inc. rose 38 cents, or 6.9 percent, to $5.88 on the Nasdaq Stock Market.

Thermogenesis Corp. saw shares rise 15 cents, or 4.6 percent, to $3.45.

Many companies in the field are developing stem cells for therapies to treat diseases such as Alzheimer's and Parkinson's. The research is also a lightning rod for debate. President Bush has vetoed a bill that would subsidize research using human embryos that are later destroyed.

Meanwhile, individual states have gone their own way, with California, Massachusetts, New York, and New Jersey all providing funding. Missouri voters narrowly passed a constitutional amendment last year to fund research.

StemCells is conducting an early stage trial for a Batten's disease treatment, a rare neurodegenerative disease that affects infants and young children.

Osiris has been given orphan drug status in Europe for its developing stem cell treatment Prochymal. That drug is being tested as a possible treatment to help prevent rejection of transplanted bone marrow and for Crohn's disease.



©

Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.  

Der hatte Cytori noch mit anderem Geschäftsfeld aufgebaut und jetzt ist sowieso mehr der AUfbau eines Konzerns mit potentiellen MRd-Umsätzen gefragt.  

Dear Friends and Investors,

Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for disease research and drug discovery, and Cytori Therapeutics (NASDAQ: CYTX: Frankfurt: XMPA), entered into a global strategic supply and commercialization agreement to offer adipose-derived stem cell-based research products to life science researchers. Invitrogen will offer Cytori's stem cell products to broaden the understanding of adult stem cells and to discover and accelerate development of preclinical applications for adipose derived stem cells.

Adipose tissue is widely recognized as a rich source of adult stem cells. A growing number of scientists are performing adipose stem cell research accounting for more than 300 scientific papers and abstracts since the seminal scientific paper describing this cell population was published in 2001. In addition, multiple clinical trials are underway globally using adipose stem cells.

"This product offering provides life science researchers access to an important and validated stem cell population," said Joydeep Goswami, Ph.D., vice president of stem cells and regenerative medicine for Invitrogen. "Adipose derived stem cells represent an attractive cell source from which to conduct regenerative medicine research, and we are excited to enter into this partnership with Cytori, a pioneer in this field."

The new products will be complemented by Invitrogen's many reagents that are used to isolate, characterize, expand and differentiate stem cells, such as the new MesenPRO RS(TM) medium, which was used to validate the adipose derived stem cell product line.

"Aligning ourselves with Invitrogen adds an additional partner offering Cytori's adipose stem cells for research purposes," said Marc H. Hedrick, M.D., president for Cytori Therapeutics. "We expect this relationship will expand the number of therapeutic applications under development with these cells as a means to broaden the opportunities for Cytori to provide stem cell-based therapies."


Regards,

Cytori Therapeutics

Contact:
Tom Baker
Tel. 858-875-5258
tbaker@cytoritx.com
--------------------------------------------------
You are subscribed to Cytori Therapeutics Investor Relations' e-mail alerts as Andreas.Keller@tuev-sued.de.

To update your e-mail and alert preferences, please visit: http://ir.cytoritx.com/...1.3918314.72e90a546edb229db8d3f23cee8037d5.
To unsubscribe, please click: http://ir.cytoritx.com/...1.3918314.72e90a546edb229db8d3f23cee8037d5.

Cytori Therapeutics
3020 Callan Road
San Diego, CA 92121  

 

http://www.fool.com/investing/high-growth/2007/05/...cret-cytori.aspx

Secret Cytori

By Mike HavrillaMay 15, 2007

Cytori Therapeutics (Nasdaq: CYTX), a micro-cap stem-cell therapy developer, is not as well-known as many of the more publicized and controversial embryonic stem-cell companies, such as Geron (Nasdaq: GERN). Cytori's proprietary Celution System is capable of processing a small sample of fat tissue from a patient in about one hour, and then delivering a concentrated dose of regenerative stem cells back to the patient for applications such as breast reconstruction and heart attacks. The Celution System avoids the ethical controversy of embryonic stem cells, instead relying on the patient's own fat tissue to provide the ultimate in personalized, regenerative stem-cell therapy without the hassle and cost of storage.

Last week, Cytori reported a first-quarter loss of $8.7 million, versus $7.5 million in the year-ago period. At the end of the first quarter, Cytori reported a cash balance of just less than $25 million. More importantly, the company plans to launch its first medical stem-cell device in Europe this year, with a market debut planned for Spain and Italy. After the European launch, Cytori hopes to be granted full FDA approval for a late 2008 product launch in the United States. In the first quarter, the company also initiated a chronic ischemia trial and made preparations to begin heart attack and breast reconstruction trials.

While Cytori may be a lesser-known player in the field of adult stem cell therapy, its unique approach of providing personalized, regenerative stem-cell therapy to patients without the cost and hassle of storage makes it a stock to watch in the coming year.

Looking for more Foolish biotech coverage? Check out the Fool's market-beating Rule Breakers newsletter service, which scours the market for innovators of all stripes and types. You can check out all of our recommendations, and get access to our message boards and exclusive content, with a 30-day free trial.

Fool contributor Mike Havrilla, R.Ph., B.S., Pharm.D., is a Rite Aid pharmacist who lives, writes, works, and enjoys running on the streets and trails in the small Pennsylvania town of Portage. He invites your comments and feedback. You can check out his picks and pans, along with the collective stock-rating wisdom of Foolish investors, at the free CAPS community home page -- where you can join in all the fun! Mike does not have a position in any company mentioned in this article. The Fool has a disclosure policy.

 

Re: Fragen an Cytori« Reply #15 on: Today at 11:09:39 AM »

---

Tom hat mir auf ein paar Fragen nach dem CC geantwortet - um 7.51 deutscher Zeit. Bei neun Stunden Zeitverschiebung war das wohl kein kurzer Arbeitstag

-> Antworten fett!!!
-> daraus folgende Interpretationen meinerseits kursiv!!!

1) I´m not sure if I understood it right that patient enrollement for Restore II (70-100 patients) at 5-10 clinical sites will take 12 months - so enrollement would be completed when the JV in Nagano goes online. That really seems extremely long for me in respect of the relatively low number of included patients. Or did Marc intend to say that enrollement + 6 month follow-up + data reporting would probably be finished until the launch in Nagano!

Marc meant to say six month enrollment plus six month follow up, but as with all trials, this is an estimate as enrolling patients that meet strict criteria can be hard to predict timing wise.

Also habe ich es im Conference Call tatsächlich falsch verstanden. Sehr schön, d.h. die Rekonstruktionsumsätze werden meiner Meinung nach in 2009 aufgrund der Kostenerstattung und einer erhöhten Akzeptanz nach Produkteinführung in 2008 gut durchstarten

2) In which timeframe following data reporting from Restore II do you expect to receive clearance from the reimbursement agencies?

Again, there are so many variables, it's hard to give a specific date, however our goal is Q4 2008 to early 2009. But it's hard to know for certain.
 
3) You always choose the phrase "prepare for market launch in Europe and Asia." Does this mean market launch in Japan in 2008? In case this does not mean Japan, which countries are you talking about where you can go to market without official approval for the device and the procedure?

To my knowledge the Roadmap anticipates Japanese approval for Celution in the first half of 2009. Is the indication "breast reconstruction" already cleared with the MHLW Agency or do you still have to file for the approval based on the Restore I data or is additional data needed? Which timeframe do you anticipate for final approval in Japan?

For 2008, you should focus your analysis mostly on Europe for therapeutic-based revenues on the Celution System. We have not disclosed any further specifics yet related to our regulatory strategy in Japan and Asia as it's something we're still navigating. However, there could be some limited sales in some of those regions if researchers were interested in using the system as lab equipment for research.

Da  bleibe ich bei meiner Aussage, dass wir wohl dort im nächsten Jahr einen Vertriebspartner haben, mit dem die Umsätze geteilt werden. Die Asiaten sind einer bessere Visionäre als die Amis +  Europäer - nice upfront

4) You repeatedly mentioned the goal to receive final 510(k) approval for Celution in the US in late 2007. Do you guys have to file an IDE thereafter for a specific indication and to run a trial in that respect to get approval from the FDA for that indication? Or is it also possible to offer Celution to the private payer market in the US following final 510(k)?

It's not clear until we have further discussion with the FDA. It's likely application-dependent. However, we definately expect we'll need to conduct trials in the US for cardiovascular applications.

ist wohl noch zu früh, das im Detail zu prognostozieren. Evlt. reicht für eine reine Vertriebserlaubnis wie im Februar für Europa erhalten ja schon die Datenauswertung von RESTORE I und RESTORE II. Die FDA-Verhandlungen werden wohl erst nach Erhalt der finalen 510(k)-Zulassung Ende dieses Jahres begonnen. Für eine Kostenerstattung durch die Reimbursement Agencies/Medicare wird aber wohl defintiv ein separater Pivotal für die USA notwendig

5) To my understanding Celution launch in Europe in 2008 is only targeting the breast reconstruction indication. That will remain a private payer market until the reimbursement agencies have reviewed the Restore II data. So  why don´t you extend the targeted patient population by also selling the device to for cosmetic applications (wrinkle removement, breast augmentation...) from the beginning. When do you anticipate to offer the procedure to the cosmetics market?

For 2008, we expect to launch under non-specific claims for reconstructive surgery, which would not specifically include breast reconstruction.

 
Für mich eindeutig die beste Antwort von allen. Das bekräftigt imho auch die etwas nebulöse Formulierung aus der Februar-PR, das man praktisch für alle "Claims" (also Indikationen) im Bereich reconstrutive surgery die Zulassung erhalten hat. Der Operateur darf die Technologie also von Anfang an so ziemlich für alle ästhetischen Schnibbeleien einsetzten (Faltenentfernung, Brustvergrößerung). Das erhöht natürlich die Patientenpopulation von Anfang an erheblich um eine zahlungskräftige und operationswillige Klientel. Jetzt bräuchte man nur noch eine Ikone a la Paris Hilton. Wenn die sich dafür unters Messer legt, können die Docs hinterher 24-Stunden-Schichten einlegen
 
6) Can you confirm that RESTORE II is also in the R&D budget for 2007? The total amount seems pretty low when compared with 2006 without any clinical trials.

It is. Keep in mind the pig studies were very expensive and we are no longer paying for those.

Zeigt noch einmal, wie akribisch wohl die Preclinicals betrieben wurden. Die Schweine-Versuche müssen richtig Geld gekostet haben. Das können keine einfachen PR-Studien gewesen sein, sondern sind mit aller wissenschaftlichen Sorgfalt angegangen worden um gute Hinweise für die momentanen Trials zu erhalten. Aus den Ergebnissen der Preclinicals kann man unschwer erraten warum sie so scharf darauf sind, die Ergebnisse von PRECISE und APOLLO so schnell zu reporten

 

Cytori Divests HYDROSORB™ Surgical Implant Product Line to Kensey Nash for $3.2 million

 

June 1, 2007, San Diego, Calif. - Cytori Therapeutics (NASDAQ: CYTX; Frankfurt: XMPA) sold its HYDROSORB™ surgical implant product line, a part of its MacroPore Biosurgery division, for $3.2 million to Kensey Nash Corporation. The line of spine and orthopedic implants will now be manufactured by Kensey Nash and will continue to be distributed by Medtronic, Inc.

"We are very pleased to achieve this planned divestiture of the HYDROSORB™ product line, which strategically increases Cytori's focus on the development and commercialization of adipose-derived regenerative cell therapies," said Christopher J. Calhoun, Chief Executive Officer for Cytori. "The divestiture will have a favorable financial impact through reduction in operating expenses and net operating loss. In addition, it represents our third non-core asset sale and brings non-dilutive cash to enable further investment into the tremendous opportunity of regenerative medicine."

As part of the transaction, Kensey Nash received related manufacturing equipment and proprietary know-how as well as ownership of regulatory filings. After a short transition period, manufacturing of the HYDROSORB™ product line will be commenced by Kensey Nash in their Exton, PA facility.

Cytori Therapeutics

Cytori Therapeutics is developing and seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious, chronic, and life threatening conditions. To provide these therapies, physicians remove a small amount of a patient's fat, also known as adipose tissue, and run it through Cytori's Celution™ System. This System quickly separates and concentrates stem and regenerative cells from adipose tissue so they may be quickly administered back to the patient about an hour later. This system will dramatically improve the way in which personalized cell-based therapies can be delivered to patients. www.cytoritx.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and prospects of our business, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties, dependence on performance of third parties, and other risks and uncertainties described (under the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2006. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

..............

http://ir.cytoritx.com/releasedetail.cfm?ReleaseID=246695

 

im Gegensatz zu Deutschland scheint die Nachricht vom Verkauf an Kensey Nash in den USA ganz gut anzukommen. Immerhin steigt der Kurs dort um 1,6%. Sehen wir das was falsch, oder ist der Verkaufspreis tatsächlich ein schlechter Witz.
Tschau Gretel  

Der Preis ist natürlich ein Witz für das Produkt, aber den Preis hat Macropore vor Jahren selbst ruiniert.

Sie haben die weltweiten Vertriebsexclusivrechte bis 2012 an Medtronic vergeben und sind dafür verpflichtet Produktionskapazitäten vorzuhalten.
Medtronic bekam den Vertrag, weil sie auch in dem Seektor tätig waren.

Und was machen die? Medtronic bestellt einfach nichts, sondern freut sich, dass ein Wettbewerber weniger im Markt ist. Ein klassisches Eigentor und die Technik ist bis 2012 nicht nutzbar. Insofern: Der Preis ist ein Witz, aber die Kensey Nash zahlen jetzt dafür, das Produkt ab 2012 selbst verkaufen zu können.  

Oder besser gefragt, wie siehst du die weitere Entwicklung der Aktie?  

Aber hier sieht es gerade spannend aus:

Über 6,50 bis 6,70 USD sollte ein zügiger Schub drin sein.

Nur bin ich mir auch nicht so sicher, ab wann die Aussicht auf Umsätze ab 2008 greift.  

so scheints. Gut prognostiziert, @ecki
 

Chart öffnen

 

um den NY-Kurs (~EUR 4,87) nachzubilden.
Ich konnte heute morgen noch ein paar Stücke unter 4,60 einsammeln.
[Grins].
 

Hammerhart:
6,65 waren 2006 die tiefs, bevor der Einbruch kam.
Ein Wochen-SK oberhalb wäre ganz klar die endgültige Bestätigung des Trendwechsels, selbst wenn ein Rückfall folgen würde.


Chart öffnen
Aktuell 6,68.

 

6,18 $   -6,18%




 

Nach candlestick im Tageschart, also mit Sicht auf ein paar Tage sieht es richtig übel aus:
Riesen Kerze hoch, abverkauf als bearishes engulfing.
Dazu Ausbruch über wichtige Marken und Downtrend und dann wieder zurück. Also Bullenfalle.

Kleine positive Sachen bleiben noch:
Im Mai waren die 6,0 dominierend. Da ist CYTX noch drüber.
Es gibt wieder ein higher high auf Mehrmonatssicht.
Aufwärtstrend bleibt intakt.

Also eher wenig Trost im Vergleich.
Das positive Szenario wäre also: Noch ne Weile quer zum Kraftsammeln zwischen 6,0 und 6,60. Bis dann der Knoten platzt.....

 

.